Abstract
Chronic obstructive pulmonary disease (COPD) is a common and disabling disease and the third leading cause of global mortality behind ischemic heart disease and stroke. Acute exacerbations of COPD accelerate lung function decline affecting the quality of life of COPD patients and moreover, remain the major contributors to morbidity and mortality of these patients. Cardiovascular comorbidities are prevalent in COPD patients and of great importance since they have a negative impact on patients’ health status. During the past few years there is an increasing interest in potential molecules that can be measured accurately and reproducibly and that can be used in COPD as biomarkers to predict clinical important outcomes such as exacerbations, hospitalizations and mortality. Such molecules have been successfully used in cardiovascular diseases and therefore, cardiac biomarkers have attracted attention for their potential use in COPD. The present review summarizes the available evidence for the use of the most important cardiac biomarkers in the evaluation of COPD severity, outcomes and management.
Keywords: Cardiac biomarkers, Chronic obstructive pulmonary disease, Acute exacerbations of chronic obstructive pulmonary disease, Comorbidities, Copeptin, B-natriuretic peptide, Adrenomedullin, Troponin T.
Current Topics in Medicinal Chemistry
Title:Cardiac Biomarkers in the Identification of Future Risk in Chronic Obstructive Pulmonary Disease
Volume: 16 Issue: 14
Author(s): Kathleen Jahn, Eleni Papakonstantinou and Daiana Stolz
Affiliation:
Keywords: Cardiac biomarkers, Chronic obstructive pulmonary disease, Acute exacerbations of chronic obstructive pulmonary disease, Comorbidities, Copeptin, B-natriuretic peptide, Adrenomedullin, Troponin T.
Abstract: Chronic obstructive pulmonary disease (COPD) is a common and disabling disease and the third leading cause of global mortality behind ischemic heart disease and stroke. Acute exacerbations of COPD accelerate lung function decline affecting the quality of life of COPD patients and moreover, remain the major contributors to morbidity and mortality of these patients. Cardiovascular comorbidities are prevalent in COPD patients and of great importance since they have a negative impact on patients’ health status. During the past few years there is an increasing interest in potential molecules that can be measured accurately and reproducibly and that can be used in COPD as biomarkers to predict clinical important outcomes such as exacerbations, hospitalizations and mortality. Such molecules have been successfully used in cardiovascular diseases and therefore, cardiac biomarkers have attracted attention for their potential use in COPD. The present review summarizes the available evidence for the use of the most important cardiac biomarkers in the evaluation of COPD severity, outcomes and management.
Export Options
About this article
Cite this article as:
Jahn Kathleen, Papakonstantinou Eleni and Stolz Daiana, Cardiac Biomarkers in the Identification of Future Risk in Chronic Obstructive Pulmonary Disease, Current Topics in Medicinal Chemistry 2016; 16 (14) . https://dx.doi.org/10.2174/1568026616666150930120233
DOI https://dx.doi.org/10.2174/1568026616666150930120233 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Amide-linked Ethanolamine Conjugate of Gemfibrozil as a Profound HDL Enhancer: Design, Synthesis, Pharmacological Screening and Docking Study
Current Drug Discovery Technologies Calcium Related Genes in Dogs as Potential Cardiac Biomarkers for the Detection of Chronic Mitral Valve Disease
Recent Patents on Biomarkers Efficient Synthesis of 6-O-methyl-scutellarein from Scutellarin via Selective Methylation
Letters in Organic Chemistry Cathinone Neurotoxicity (“The “3Ms”)
Current Neuropharmacology Systemic Lupus Erythematosus: Correlation Between Immunodysregulation and Clinical Manifestations
Current Rheumatology Reviews Nitroimidazole Radiopharmaceuticals in Bioimaging: Part I: Synthesis and Imaging Applications
Current Radiopharmaceuticals Characteristics Other than the Diagnostic Criteria Associated with Metabolic Syndrome: An Overview
Current Vascular Pharmacology Synthesis and Evaluation of Compounds Containing 4-arylpiperazinyl Moieties Linked to a 2-(pyridin-3-yl)-1H-benzimidazole as p38 MAP Kinase Inhibitors
Letters in Drug Design & Discovery Understanding and Avoiding Antiretroviral Adverse Events
Current Pharmaceutical Design Peri-Procedural Care of Renal Nerve Ablation Candidates
Current Clinical Pharmacology Recent Advances in Image-Based Stem-Cell Labeling and Tracking, and Scaffold-Based Organ Development in Cardiovascular Disease
Recent Patents on Medical Imaging Potential Role of Polyphenols in the Prevention of Cardiovascular Diseases: Molecular Bases
Current Medicinal Chemistry Coronary Pressure Measurement Based Decision Making for Percutaneous Coronary Intervention
Current Cardiology Reviews Geriatric Evaluation of Oncological Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot Topic: Inflammation as Target for Pharmaceutical Intervention in Cancer (Executive Editors: R.M. Schiffelers and K.E. de Visser)]
Current Pharmaceutical Design Lipid Profile Results after Cardiovascular Prevention Programme: Euroaction Model in Spain
Endocrine, Metabolic & Immune Disorders - Drug Targets G Protein-Coupled Receptors in Regulation of Body Weight
CNS & Neurological Disorders - Drug Targets Medical Treatment of Critical Limb Ischemia: Current State and Future Directions
Current Vascular Pharmacology Mutations of mtDNA in some Vascular and Metabolic Diseases
Current Pharmaceutical Design Evaluation of the Possible Contribution of Antioxidants Administration in Metabolic Syndrome
Current Pharmaceutical Design